<DOC>
	<DOCNO>NCT01485068</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Danubio Paclitaxel Eluting Balloon treatment In-Stent Restenosis lesion native coronary artery .</brief_summary>
	<brief_title>Safety Efficacy Study DANUBIO Paclitaxel Eluting Balloon In-Stent Restenosis Lesions ( DEBREST )</brief_title>
	<detailed_description>The DEBREST clinical trial prospective , non-randomized , multicenter , interventional study evaluate investigational Danubio Paclitaxel Eluting Coronary Balloon patient in-stent restenosis ( ISR ) lesion ( ) reference vessel diameter ≥2.5 mm ≤3.5 mm . The trial allow treatment two ISR ( either Bare Metal Stent ( BMS ) Drug Eluting Stent ( DES ) ISR ) per patient native coronary artery mandatory predilatation conventional balloon . The DEBREST clinical trial enroll 60 patient . All patient receive Quantitative Coronary Angiography ( QCA ) Drug-Eluting Balloon ( DEB ) inflation 6 month follow-up . All patient clinical follow-up 1 , 6 12 month .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Restenotic lesion native coronary artery . 2 . First ISR BMS DES implantation . 3 . Reference diameter &gt; 2.5 ≤ 3.5mm . 4 . Target lesion length : ≤ 21mm . 5 . Up three restenotic lesion per patient . 6 . Single restenotic lesion per vessel . 7 . The lesion must treat trial device Danubio . 8 . During index procedure , case 1 . Treatment lesion vessel target vessel , 2 . Treatment lesion target vessel proximal distal target restenotic lesion , The treatment nontarget lesion must successfully perform DrugEluting Stent treatment target lesion ( residual stenosis &lt; 30 % ; stent well deploy ; residual dissection ; normal TIMI flow ; chest pain ; ECG unchanged compare preprocedural ECG ) . 9 . Successful predilatation conventional balloon provide good angiographic result ( i.e . absence dissection , TIMI &gt; III ) . 10 . The patient least 18 year age . 11 . Non menopausal woman must provide negative pregnancy test use double contraception end study . 12 . The patient clinical evidence ischemic heart disease , stable unstable angina sign ischemia , silent ischemia , positive functional test . 13 . The patient acceptable candidate percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery . 14 . The patient patient 's legal representative inform nature trial agrees provision provide write informed consent approve Ethics Committee ( EC ) . 15 . The patient agree return research facility require angiographic postprocedure followup visit 6 month . 1 . Bifurcation lesion ( ) include leave main . 2 . The Danubio cover beyond lesion proximally distally &lt; 2 mm . 3 . Heavily calcified lesion . 4 . Severe tortuous lesion . 5 . Evidence extensive thrombosis dissection within target vessel intervention . 6 . Documented Left Ventricular Ejection Fraction ( LVEF ) &lt; 30 % recent evaluation . 7 . A known hypersensitivity contraindication aspirin , heparin bivaluridin , ticlopidine clopidogrel , paclitaxel drug similar class , contrast medium , adequately premedicated . 8 . Chronic total occlusion ( CTO ) . 9 . A serum creatinine level &gt; 2.0 mg/dL within seven day prior index procedure . 10 . Evidence acute MI within 72 hour intend index procedure ( accord ARC definition ) . 11 . Planned PCI vessel within 30 day postprocedure . 12 . Surgery 30 day prior PCI anticipate surgery 6months post PCI . 13 . During index procedure , target lesion require treatment device PTCA prior use Danubio ( include limit cut balloon , atherectomy , laser , thrombectomy , etc. ) . 14 . Second restenotic lesion require treatment target vessel . 15 . History stroke transient ischemic attack ( TIA ) within prior 6 month 16 . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month . 17 . History bleed diathesis coagulopathy refuse blood transfusion . 18 . Concurrent medical condition life expectancy le 12 month . 19 . Any previous plan treatment target vessel antirestenotic therapy include , limited brachytherapy . 20 . Currently participate investigational drug another device trial complete primary endpoint clinically interfere current trial endpoint ; require coronary angiography , IVUS coronary artery imaging procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Restenosis</keyword>
	<keyword>Paclitaxel-eluting balloon</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Coronary artery stenosis</keyword>
</DOC>